DAVENPORT & Co LLC Sells 435,679 Shares of Novo Nordisk A/S $NVO

DAVENPORT & Co LLC lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 16.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,206,819 shares of the company’s stock after selling 435,679 shares during the period. DAVENPORT & Co LLC’s holdings in Novo Nordisk A/S were worth $112,530,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Beacon Financial Group boosted its holdings in shares of Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the period. Kavar Capital Partners Group LLC increased its holdings in Novo Nordisk A/S by 0.6% during the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after purchasing an additional 200 shares during the period. SeaBridge Investment Advisors LLC raised its position in Novo Nordisk A/S by 5.7% during the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after purchasing an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC lifted its holdings in Novo Nordisk A/S by 1.0% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after buying an additional 200 shares during the period. Finally, Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on NVO shares. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a report on Tuesday, March 10th. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 price objective on the stock. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a research report on Tuesday, March 3rd. Four research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Trading Up 0.2%

NVO opened at $36.90 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $81.44. The stock has a market cap of $164.75 billion, a PE ratio of 10.63 and a beta of 0.73. The business has a 50 day moving average of $47.31 and a 200-day moving average of $50.81.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo advanced its partnered oral obesity program by starting a Phase I study of LX9851 (licensed from Lexicon), expanding its non‑incretin pipeline and preserving upside beyond semaglutide-class drugs. The deal also contains near‑term milestone payments and downstream royalties, which de‑risks incremental pipeline value. LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
• Positive Sentiment: The FDA cleared a higher dose formulation of Wegovy (Wegovy HD), widening the label and potentially increasing per‑patient efficacy and lifetime value for the GLP‑1 franchise — a near‑term catalyst for revenue growth and market share. FDA clears higher dose of Wegovy as Novo Nordisk ramps up $4B North Carolina expansion
• Positive Sentiment: Management is executing a share repurchase program (part of a DKK15bn 12‑month plan), which supports EPS and signals capital allocation discipline. Buybacks can be a floor for the stock amid near‑term revenue uncertainty. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Novo’s renewed distribution partnerships (e.g., with telehealth platforms) broaden patient access and may accelerate prescriptions but also shift the margin mix and channel dynamics; watch execution and pricing terms. Seeking Alpha coverage on channel deals
• Negative Sentiment: Analyst Jefferies trimmed its price target and kept a Hold rating, flagging mounting GLP‑1 pricing erosion, uncertainty around the oral Wegovy launch trajectory and risk of cannibalization across the portfolio — a driver of near‑term downward pressure on sentiment. Jefferies trims Novo Nordisk target
• Negative Sentiment: Semaglutide patent loss in India triggered a flood of very low‑price generics (Ozempic/Wegovy copies), sharply undercutting prices there and highlighting how regional patent expiries and low‑cost competition can erode pricing and set precedent for other markets. This increases medium‑term pricing risk globally. Indian generics flood market for Ozempic/Wegovy

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.